Myokines for treating cell proliferative and metabolic diseases and disorders

Patent metadata

Field	Value
Publication number	US-2020362001-A1
Application number	US-202016877275-A
Country	US
Kind code	A1
Filing date	May 18, 2020
Priority date	May 16, 2019
Publication date	Nov 19, 2020
Grant date	—

Abstract

Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.

First claim

We claim:

1 . An isolated fraction of myokines comprising an effective amount of one or more myokines for treating and/or preventing cell proliferative diseases ordisorders and/or metabolic diseases or disorders, wherein (i) the one or more myokines have a molecular weight greater than about 10 kDa; and/or (ii) the one or more myokines comprise myostatin, metrnl, or both of myostain and metrnl.

2 . The isolated fraction of myokines of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for treating colorectal cancer.

3 . The isolated fraction of myokines of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for treating a cancer whose growth is associated with chromatin density.

4 . The isolated fraction of myokines of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for treating a cancer whose growth is associated with epidermal growth factor receptor (EGRF) activity.

5 . The isolated fraction of myokines of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for inhibiting epidermal growth factor receptor (EGRF) activity.

6 . A pharmaceutical composition comprising the isolated fraction of myokines of claim 1 and a suitable pharmaceutical carrier.

7 . A kit for treating and/or preventing cell proliferative diseases and disorders, the kit comprising a combination of components comprising: (i) the isolated fraction of myokines of claim 1 ; and a chemotherapeutic drug for treating and/or preventing the cell proliferative disease or disorder.

8 . The kit of claim 7 , wherein the kit comprises myostatin and a platinum-based chemotherapeutic agent.

9 . The kit of claim 7 , wherein the kit comprises myostatin and oxaliplatin.

10 . The kit of claim 7 , wherein the kit comprises metrnl and a platinum-based chemotherapeutic agent.

11 . The kit of claim 7 , wherein the kit comprises metrnl and oxaliplatin.

12 . A method for treating and/or preventing a cell proliferative disease or disorder in a subject in need thereof, the method comprising administering to the subject the isolated fraction of myokines of claim 1 or a pharmaceutical formulation thereof.

13 . The method of claim 12 , wherein the cell proliferative disease or disorder is colorectal cancer.

14 . A method for treating and/or preventing a cell proliferative disease or disorder in a subject in need thereof, the method comprising administering to the subject the components of the kit of claim 8 , or a pharmaceutical formulation thereof.

15 . A method for treating and/or preventing a cell proliferative disease or disorder in a subject in need thereof, the method comprising administering to the subject the subject the isolated fraction of myokines of claim 1 or a pharmaceutical formulation thereof, and administering to the subject a chemotherapeutic drug for treating and/or preventing the cell proliferative disease or disorder.

16 . The method of claim 15 , wherein the cell proliferative disease or disorder is colorectal cancer.

17 . The method of claim 15 , wherein the isolated fraction of myokines comprises myostatin.

18 . The method of claim 15 , wherein the isolated fraction of myokines comprises metrnl.

19 . The method of claim 15 , wherein the chemotherapeutic drug is a platinum-based drug.

20 . A method for preparing an isolated myokine fraction, the method comprising (a) treating myotubules in a media culture with a electrostimulation wherein one or more of the following conditions are met (i) the myotubules are treated with electrostimulation for at least about 4 hours; (ii) the myotubules are treated with a voltage of at least about 20 V; and the myotubules are treated with a frequency of at least about 2 Hz; (b) isolating a myokine fraction released from the electrostimulated myotubules.

Assignees

• Univ Northwestern

Inventors

• Roy Hemant K
• Backman Vadim

Classifications

• A61K38/18

  Growth factors; Growth regulators · CPC title

• C07K14/52

  Cytokines; Lymphokines; Interferons · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title